vs

Side-by-side financial comparison of Finwise Bancorp (FINW) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $42.7M, roughly 1.8× Finwise Bancorp). Over the past eight quarters, Finwise Bancorp's revenue compounded faster (47.0% CAGR vs -34.4%).

Finwise Bancorp is a U.S.-based financial holding company that operates primarily through its community banking subsidiary. It offers a full suite of retail and commercial financial services, including deposit accounts, personal loans, mortgage products, small business financing, and wealth management solutions, serving local retail consumers and small to medium-sized business clients across its regional operating markets.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

FINW vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.8× larger
MED
$75.1M
$42.7M
FINW
Faster 2-yr revenue CAGR
FINW
FINW
Annualised
FINW
47.0%
-34.4%
MED

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FINW
FINW
MED
MED
Revenue
$42.7M
$75.1M
Net Profit
$2.7M
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
6.4%
Revenue YoY
-36.9%
Net Profit YoY
EPS (diluted)
$0.20
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FINW
FINW
MED
MED
Q1 26
$42.7M
Q4 25
$46.9M
$75.1M
Q3 25
$36.7M
$89.4M
Q2 25
$25.1M
$105.6M
Q1 25
$22.1M
$115.7M
Q4 24
$21.1M
$119.0M
Q3 24
$20.8M
$140.2M
Q2 24
$19.8M
$168.6M
Net Profit
FINW
FINW
MED
MED
Q1 26
$2.7M
Q4 25
$3.9M
Q3 25
$4.9M
$-2.3M
Q2 25
$4.1M
$2.5M
Q1 25
$3.2M
$-772.0K
Q4 24
$2.8M
Q3 24
$3.5M
$1.1M
Q2 24
$3.2M
$-8.2M
Gross Margin
FINW
FINW
MED
MED
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
FINW
FINW
MED
MED
Q1 26
Q4 25
11.7%
-10.4%
Q3 25
17.5%
-4.6%
Q2 25
21.7%
-1.0%
Q1 25
20.1%
-1.1%
Q4 24
17.5%
0.6%
Q3 24
22.2%
1.5%
Q2 24
21.1%
-4.7%
Net Margin
FINW
FINW
MED
MED
Q1 26
6.4%
Q4 25
8.4%
Q3 25
13.3%
-2.5%
Q2 25
16.3%
2.3%
Q1 25
14.4%
-0.7%
Q4 24
13.2%
Q3 24
16.6%
0.8%
Q2 24
16.1%
-4.8%
EPS (diluted)
FINW
FINW
MED
MED
Q1 26
$0.20
Q4 25
$0.27
$-1.64
Q3 25
$0.34
$-0.21
Q2 25
$0.29
$0.22
Q1 25
$0.23
$-0.07
Q4 24
$0.19
$0.08
Q3 24
$0.25
$0.10
Q2 24
$0.24
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FINW
FINW
MED
MED
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$196.6M
$198.9M
Total Assets
$899.4M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FINW
FINW
MED
MED
Q1 26
Q4 25
$163.4M
$167.3M
Q3 25
$105.6M
$173.5M
Q2 25
$90.1M
$162.7M
Q1 25
$120.3M
$164.6M
Q4 24
$109.2M
$162.3M
Q3 24
$85.8M
$170.0M
Q2 24
$89.0M
$163.5M
Stockholders' Equity
FINW
FINW
MED
MED
Q1 26
$196.6M
Q4 25
$193.2M
$198.9M
Q3 25
$187.8M
$214.7M
Q2 25
$182.0M
$216.0M
Q1 25
$177.4M
$211.0M
Q4 24
$173.7M
$210.1M
Q3 24
$170.4M
$207.3M
Q2 24
$165.8M
$205.3M
Total Assets
FINW
FINW
MED
MED
Q1 26
$899.4M
Q4 25
$977.1M
$248.0M
Q3 25
$899.9M
$268.2M
Q2 25
$842.5M
$269.3M
Q1 25
$804.1M
$280.0M
Q4 24
$746.0M
$284.2M
Q3 24
$683.0M
$291.2M
Q2 24
$617.8M
$293.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FINW
FINW
MED
MED
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FINW
FINW
MED
MED
Q1 26
Q4 25
$-28.4M
$-5.3M
Q3 25
$3.5M
$12.1M
Q2 25
$-18.3M
$-3.4M
Q1 25
$-21.6M
$3.4M
Q4 24
$-15.0M
$-4.9M
Q3 24
$-9.8M
$9.1M
Q2 24
$-7.6M
$13.1M
Free Cash Flow
FINW
FINW
MED
MED
Q1 26
Q4 25
$-28.6M
$-6.6M
Q3 25
$3.4M
$10.8M
Q2 25
$-19.8M
$-4.8M
Q1 25
$-23.3M
$1.9M
Q4 24
$-16.1M
$-7.2M
Q3 24
$-13.4M
$7.7M
Q2 24
$-7.7M
$11.1M
FCF Margin
FINW
FINW
MED
MED
Q1 26
Q4 25
-61.1%
-8.8%
Q3 25
9.4%
12.0%
Q2 25
-79.0%
-4.5%
Q1 25
-105.3%
1.6%
Q4 24
-76.0%
-6.1%
Q3 24
-64.3%
5.5%
Q2 24
-38.7%
6.6%
Capex Intensity
FINW
FINW
MED
MED
Q1 26
Q4 25
0.5%
1.8%
Q3 25
0.1%
1.5%
Q2 25
5.8%
1.3%
Q1 25
7.4%
1.3%
Q4 24
5.1%
1.9%
Q3 24
17.2%
1.0%
Q2 24
0.3%
1.1%
Cash Conversion
FINW
FINW
MED
MED
Q1 26
Q4 25
-7.26×
Q3 25
0.71×
Q2 25
-4.48×
-1.36×
Q1 25
-6.78×
Q4 24
-5.37×
Q3 24
-2.84×
8.04×
Q2 24
-2.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FINW
FINW

Net Interest Income$28.1M66%
Noninterest Income$14.6M34%

MED
MED

Segment breakdown not available.

Related Comparisons